Glofitamab

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) [1][2][3][4].

2229047-91-8

RO7082859; RG-6026

12352203

CD20; CD3

Inhibitory Antibodies

Immunology/Inflammation

Cancer-programmed cell death

Cancer; Inflammation/Immunology

https://www.medchemexpress.com/glofitamab.html

99.80

H2O

[Glofitamab]

(194 kDa)

[1]Hutchings M, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39 (18) :1959-1970. |[2]Bröske AE, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Blood Adv. 2022;6 (3) :1025-1037. |[3]Frances N, et al. Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. J Pharm Sci. 2022 Apr;111 (4) :1208-1218. |[4]Apollonio B, et al. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma. J Clin Invest. 2023 Jul 3;133 (13) :e166070.|[5]Cremasco F, et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS One. 2021 Jan 6;16 (1) :e0241091.

Dry Ice

Store at -80°C for 2 years

Inhibitory Antibodies